Is SoFi Stock a Buy Under $20?
After briefly flirting with penny‑stock territory during the 2022 bear…
Buy
56
SGHT Quote, Financials, Valuation and Earnings
Last price:
$4.30
Seasonality move
:
-30.62%
Day range:
$4.17 - $4.34
52-week range:
$2.03 - $8.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.78x
P/B ratio:
2.86x
Volume:
840.4K
Avg. volume:
174.1K
1-year change:
-34.25%
Market cap:
$222.3M
Revenue:
$79.9M
EPS (TTM):
-$0.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SGHT
Sight Sciences
|
$18.2M | -$0.27 | -14.5% | -10.02% | $3.77 |
|
ADGM
Adagio Medical Holdings
|
-- | -- | -- | -- | -- |
|
AIMD
Ainos
|
-- | -- | -- | -- | -- |
|
INBS
Intelligent Bio Solutions
|
$1.4M | -- | 160.36% | -- | -- |
|
LAB
Standard BioTools
|
$39.8M | -$0.04 | 7.07% | -66.67% | $2.38 |
|
LNSR
LENSAR
|
$16.6M | -$0.08 | 30.98% | -90.51% | $15.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SGHT
Sight Sciences
|
$4.30 | $3.77 | $222.3M | -- | $0.00 | 0% | 2.78x |
|
ADGM
Adagio Medical Holdings
|
$1.29 | -- | $19.8M | 218.00x | $0.00 | 0% | 88.90x |
|
AIMD
Ainos
|
$2.50 | -- | $10.4M | -- | $0.00 | 0% | 56.59x |
|
INBS
Intelligent Bio Solutions
|
$1.53 | -- | $10.6M | -- | $0.00 | 0% | 2.29x |
|
LAB
Standard BioTools
|
$1.19 | $2.38 | $429.9M | -- | $0.00 | 0% | 2.62x |
|
LNSR
LENSAR
|
$12.76 | $15.00 | $150.5M | -- | $0.00 | 0% | 2.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SGHT
Sight Sciences
|
33.77% | 0.427 | 32.1% | 9.75x |
|
ADGM
Adagio Medical Holdings
|
-- | 0.405 | -- | -- |
|
AIMD
Ainos
|
47.77% | 2.165 | 141.91% | 1.73x |
|
INBS
Intelligent Bio Solutions
|
6.51% | 3.270 | 3.7% | 0.84x |
|
LAB
Standard BioTools
|
0.07% | -0.784 | 0.07% | 5.22x |
|
LNSR
LENSAR
|
-- | -0.430 | -- | 1.20x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SGHT
Sight Sciences
|
$15.1M | -$13.9M | -37.91% | -52.44% | -73.4% | -$11.6M |
|
ADGM
Adagio Medical Holdings
|
-$253K | -$7.4M | -- | -- | -- | -$7.5M |
|
AIMD
Ainos
|
$88K | -$3.2M | -50.84% | -82.37% | -2924.08% | -$1.3M |
|
INBS
Intelligent Bio Solutions
|
$341.4K | -$2.6M | -140.31% | -149.7% | -347.89% | -$2.8M |
|
LAB
Standard BioTools
|
$19.7M | -$30.3M | -24.87% | -26.52% | -64.18% | -$35.3M |
|
LNSR
LENSAR
|
$7.1M | -$5.8M | -464.33% | -464.33% | -40.89% | -$6.9M |
Sight Sciences vs. Competitors
-
Which has Higher Returns SGHT or ADGM?
Adagio Medical Holdings has a net margin of -80.84% compared to Sight Sciences's net margin of --. Sight Sciences's return on equity of -52.44% beat Adagio Medical Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SGHTSight Sciences86.21% -$0.28 $117.2M ADGMAdagio Medical Holdings-- -$0.51 -- -
What do Analysts Say About SGHT or ADGM?
Sight Sciences has a consensus price target of $3.77, signalling downside risk potential of -12.4%. On the other hand Adagio Medical Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Sight Sciences has higher upside potential than Adagio Medical Holdings, analysts believe Sight Sciences is more attractive than Adagio Medical Holdings.
Company Buy Ratings Hold Ratings Sell Ratings SGHTSight Sciences2 5 0 ADGMAdagio Medical Holdings0 0 0 -
Is SGHT or ADGM More Risky?
Sight Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagio Medical Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SGHT or ADGM?
Sight Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sight Sciences pays -- of its earnings as a dividend. Adagio Medical Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SGHT or ADGM?
Sight Sciences quarterly revenues are $17.5M, which are larger than Adagio Medical Holdings quarterly revenues of --. Sight Sciences's net income of -$14.2M is lower than Adagio Medical Holdings's net income of -$7.7M. Notably, Sight Sciences's price-to-earnings ratio is -- while Adagio Medical Holdings's PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sight Sciences is 2.78x versus 88.90x for Adagio Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGHTSight Sciences2.78x -- $17.5M -$14.2M ADGMAdagio Medical Holdings88.90x 218.00x -- -$7.7M
-
Which has Higher Returns SGHT or AIMD?
Ainos has a net margin of -80.84% compared to Sight Sciences's net margin of -3093.98%. Sight Sciences's return on equity of -52.44% beat Ainos's return on equity of -82.37%.
Company Gross Margin Earnings Per Share Invested Capital SGHTSight Sciences86.21% -$0.28 $117.2M AIMDAinos82.83% -$0.21 $25.1M -
What do Analysts Say About SGHT or AIMD?
Sight Sciences has a consensus price target of $3.77, signalling downside risk potential of -12.4%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Sight Sciences has higher upside potential than Ainos, analysts believe Sight Sciences is more attractive than Ainos.
Company Buy Ratings Hold Ratings Sell Ratings SGHTSight Sciences2 5 0 AIMDAinos0 0 0 -
Is SGHT or AIMD More Risky?
Sight Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 2.202, suggesting its more volatile than the S&P 500 by 120.24%.
-
Which is a Better Dividend Stock SGHT or AIMD?
Sight Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sight Sciences pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SGHT or AIMD?
Sight Sciences quarterly revenues are $17.5M, which are larger than Ainos quarterly revenues of $106.2K. Sight Sciences's net income of -$14.2M is lower than Ainos's net income of -$3.3M. Notably, Sight Sciences's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sight Sciences is 2.78x versus 56.59x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGHTSight Sciences2.78x -- $17.5M -$14.2M AIMDAinos56.59x -- $106.2K -$3.3M
-
Which has Higher Returns SGHT or INBS?
Intelligent Bio Solutions has a net margin of -80.84% compared to Sight Sciences's net margin of -348.97%. Sight Sciences's return on equity of -52.44% beat Intelligent Bio Solutions's return on equity of -149.7%.
Company Gross Margin Earnings Per Share Invested Capital SGHTSight Sciences86.21% -$0.28 $117.2M INBSIntelligent Bio Solutions46.84% -$0.44 $5.3M -
What do Analysts Say About SGHT or INBS?
Sight Sciences has a consensus price target of $3.77, signalling downside risk potential of -12.4%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 684.31%. Given that Intelligent Bio Solutions has higher upside potential than Sight Sciences, analysts believe Intelligent Bio Solutions is more attractive than Sight Sciences.
Company Buy Ratings Hold Ratings Sell Ratings SGHTSight Sciences2 5 0 INBSIntelligent Bio Solutions0 0 0 -
Is SGHT or INBS More Risky?
Sight Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SGHT or INBS?
Sight Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sight Sciences pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SGHT or INBS?
Sight Sciences quarterly revenues are $17.5M, which are larger than Intelligent Bio Solutions quarterly revenues of $728.9K. Sight Sciences's net income of -$14.2M is lower than Intelligent Bio Solutions's net income of -$2.5M. Notably, Sight Sciences's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sight Sciences is 2.78x versus 2.29x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGHTSight Sciences2.78x -- $17.5M -$14.2M INBSIntelligent Bio Solutions2.29x -- $728.9K -$2.5M
-
Which has Higher Returns SGHT or LAB?
Standard BioTools has a net margin of -80.84% compared to Sight Sciences's net margin of -63.81%. Sight Sciences's return on equity of -52.44% beat Standard BioTools's return on equity of -26.52%.
Company Gross Margin Earnings Per Share Invested Capital SGHTSight Sciences86.21% -$0.28 $117.2M LABStandard BioTools48.39% -$0.07 $454.9M -
What do Analysts Say About SGHT or LAB?
Sight Sciences has a consensus price target of $3.77, signalling downside risk potential of -12.4%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 99.58%. Given that Standard BioTools has higher upside potential than Sight Sciences, analysts believe Standard BioTools is more attractive than Sight Sciences.
Company Buy Ratings Hold Ratings Sell Ratings SGHTSight Sciences2 5 0 LABStandard BioTools2 1 0 -
Is SGHT or LAB More Risky?
Sight Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.
-
Which is a Better Dividend Stock SGHT or LAB?
Sight Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sight Sciences pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SGHT or LAB?
Sight Sciences quarterly revenues are $17.5M, which are smaller than Standard BioTools quarterly revenues of $40.8M. Sight Sciences's net income of -$14.2M is higher than Standard BioTools's net income of -$26M. Notably, Sight Sciences's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sight Sciences is 2.78x versus 2.62x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGHTSight Sciences2.78x -- $17.5M -$14.2M LABStandard BioTools2.62x -- $40.8M -$26M
-
Which has Higher Returns SGHT or LNSR?
LENSAR has a net margin of -80.84% compared to Sight Sciences's net margin of -193.13%. Sight Sciences's return on equity of -52.44% beat LENSAR's return on equity of -464.33%.
Company Gross Margin Earnings Per Share Invested Capital SGHTSight Sciences86.21% -$0.28 $117.2M LNSRLENSAR50.32% -$2.32 -$22.1M -
What do Analysts Say About SGHT or LNSR?
Sight Sciences has a consensus price target of $3.77, signalling downside risk potential of -12.4%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 17.56%. Given that LENSAR has higher upside potential than Sight Sciences, analysts believe LENSAR is more attractive than Sight Sciences.
Company Buy Ratings Hold Ratings Sell Ratings SGHTSight Sciences2 5 0 LNSRLENSAR0 2 0 -
Is SGHT or LNSR More Risky?
Sight Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SGHT or LNSR?
Sight Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sight Sciences pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SGHT or LNSR?
Sight Sciences quarterly revenues are $17.5M, which are larger than LENSAR quarterly revenues of $14.2M. Sight Sciences's net income of -$14.2M is higher than LENSAR's net income of -$27.3M. Notably, Sight Sciences's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sight Sciences is 2.78x versus 2.60x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGHTSight Sciences2.78x -- $17.5M -$14.2M LNSRLENSAR2.60x -- $14.2M -$27.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Apple Stock Not Joining the Broader Market Rally?
The S&P 500 has sprinted 4.92% higher so far in…
Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
